Dr. Reddy's Laboratories has launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic equivalent generic version of Avelox (moxifloxacin HCI) tablets 400 mg in the US market on March 04, 2014, following the approval by the United States Food & Drug Administration (USFDA).
The Avelox tablets brand had U.S. sales of approximately $195 million for the most recent twelve months ending in December 2013 according to IMS Health.
Dr. Reddy's Moxifloxacin Hydrochloride Tablets, 400 mg is available in bottle counts of 30.
Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
